Mainz Biomed (MYNZ) Stock Price, News & Analysis

Company Overview

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

Key Stats

• Today's Range: $0.21 to $0.22
• 50-Day Range: $0.20 to $0.38
• 52-Week Range: $0.19 to $1.79
• Volume: 1.04 million shs
• Average Volume: 1.25 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Moderate Buy

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Mainz Biomed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.71% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mainz Biomed has recently decreased by 10.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.71% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mainz Biomed has recently decreased by 10.59%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Mainz Biomed this week, compared to 1 article on an average week.

Search Interest

9 people have searched for MYNZ on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.

MarketBeat Follows

1 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.20% of the stock of Mainz Biomed is held by insiders. A high percentage of insider ownership can be a sign of company health.

MYNZ Stock Analysis - Frequently Asked Questions

How have MYNZ shares performed this year?

Mainz Biomed's stock was trading at $1.16 at the beginning of 2024. Since then, MYNZ shares have decreased by 80.7% and is now trading at $0.2240.
View the best growth stocks for 2024 here.

How were Mainz Biomed's earnings last quarter?

Mainz Biomed (NASDAQ:MYNZ) posted its quarterly earnings results on Tuesday, August, 15th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.14. The firm had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.25 million.

When did Mainz Biomed IPO?

Mainz Biomed (MYNZ) raised $10 million in an initial public offering (IPO) on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO.

How do I buy shares of Mainz Biomed?

Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mainz Biomed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mainz Biomed investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), Ford Motor (F), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD) and PayPal (PYPL).

Company Calendar

• Last Earnings: 8/15/2023
• Today: 11/21/2024
• Next Earnings (Estimated): 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MYNZ
• CUSIP: N/A
• CIK: 1874252
• Web: mainzbiomed.com
• Phone: 49-6131-554-2860
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +1,336.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $900,000.00
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.07